<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11764">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953782</url>
  </required_header>
  <id_info>
    <org_study_id>5F9004</org_study_id>
    <nct_id>NCT02953782</nct_id>
  </id_info>
  <brief_title>Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forty Seven, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forty Seven, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate Hu5F9-G4 in combination with cetuximab. Hu5F9-G4 is a monoclonal
      antibody which is designed to block a protein called CD47, which is widely expressed on
      human cancer cells. Blocking CD47 with Hu5F9-G4 may enable the body's immune system to find
      and destroy the cancer cells. Cetuximab is a monoclonal antibody drug that is used for
      treatment of certain types of colorectal cancer as well as head and neck cancer.

      The major aims of the study are: (Phase 1b) to define the safety profile and to determine a
      recommended Phase 2 dose for Hu5F9-G4 in combination with cetuximab, and (Phase 2) to
      evaluate the objective response rate of Hu5F9-G4 in combination with cetuximab in patients
      with advanced colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (Number of participants with a DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicities (DLTs) (Phase 1b only) Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (as defined by RECIST Version 1.1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 2: Objective response as defined by RECIST Version 1.1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1b, patients with advanced solid tumors will receive escalating doses of Hu5F9-G4 in combination with cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 KRAS mutant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, patients with advanced KRAS mutant colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 KRAS wild-type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, patients with advanced KRAS wild-type colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hu5F9-G4</intervention_name>
    <description>Hu5F9-G4 will be administered weekly.</description>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_label>Phase 2 KRAS mutant</arm_group_label>
    <arm_group_label>Phase 2 KRAS wild-type</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab will be administered weekly.</description>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_label>Phase 2 KRAS mutant</arm_group_label>
    <arm_group_label>Phase 2 KRAS wild-type</arm_group_label>
    <other_name>ERBITUX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological Diagnosis

               -  Phase 1b only: Advanced solid malignancy with an emphasis on colorectal, head
                  and neck, breast, pancreatic and ovarian cancers who have been treated with at
                  least one regimen of prior systemic therapy, or who refuse systemic therapy, and
                  for which there is no curative therapy available.

               -  Phase 2:

          -  KRAS Mutant CRC: Advanced KRAS mutant CRC who have progressed or are ineligible for
             both irinotecan and oxaliplatin based chemotherapy

          -  KRAS Wild Type CRC: Advanced KRAS wild type CRC who have progressed or are ineligible
             for both irinotecan and oxaliplatin based chemotherapy and who are relapsed or
             refractory to at least 1 prior systemic therapy that included an anti-EGFR antibody,
             such as cetuximab, panitumumab or others.

          -  Adequate performance status and hematological, liver, and kidney function

          -  Phase 2 only: Willing to consent to 1 mandatory pre-treatment and 1 on-treatment
             tumor biopsy

        Exclusion Criteria:

          -  Active brain metastases

          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting
             agents.

          -  Phase 2 only: second malignancy within the last 3 years.

          -  Known active or chronic hepatitis B or C infection or HIV

          -  Pregnancy or active breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Takimoto, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Forty Seven, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Takimoto, MD PhD</last_name>
    <phone>650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hassan Movahhed</last_name>
    <phone>650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski, BS CCRP</last_name>
      <phone>616-954-5554</phone>
      <email>kathy.estkowski@start.stoh.com</email>
    </contact>
    <contact_backup>
      <last_name>Yvette C Cole, RN BSN OCN</last_name>
      <phone>616-954-5554</phone>
      <email>Yvette.cole@start.stoh.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Bendell, MD</last_name>
    </contact>
    <contact_backup>
      <phone>615-329-7274</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>START Center for Cancer Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN MSN</last_name>
      <phone>210-593-5252</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 15, 2016</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms, Hu5F9-G4, CD47, cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
